FDA approvals, clinical trial results, insurance coverage changes, and breakthrough research in transcranial magnetic stimulation.
Our pick of the latest must-read TMS news.
BrainsWay presented the largest real-world dataset to date on Deep TMS for patients with comorbid PTSD and major depressive disorder. Among 462 patients, 83.5% achieved a PTSD response and depression symptoms improved substantially.
Read full coverage →63 stories on FDA approvals, clinical trials, and emerging research.
BrainsWay presented the largest real-world dataset to date on Deep TMS for patients with comorbid PTSD and major depressive disorder. Among 462 patients, 83.5% achieved a PTSD response and depression symptoms improved substantially.
Read more →BrainsWay announced that favorable U.S. medical-policy coverage for its SWIFT accelerated Deep TMS protocol has grown to more than 57 million covered lives, after a new South Carolina policy added roughly 2 million members.
Read more →Neuronetics promoted Cory Anderson from Chief Technology Officer to Executive Vice President and General Manager of Greenbrook, the large TMS and Spravato clinic network the company acquired in late 2024. The move took effect July 1, 2026.
Read more →Wave Neuroscience received FDA 510(k) clearance for its MeRT (Magnetic EEG-guided Resonance Therapy) system to treat PTSD. It is the first FDA-cleared personalized, biomarker-guided neuromodulation technology for the condition.
Read more →BrainsWay presented the first prospective 12-month durability data for its SWIFT accelerated Deep TMS protocol at the Clinical TMS Society Annual Meeting. Preliminary analysis showed an over-80% remission rate one year after treatment.
Read more →The Clinical TMS Society held its 2026 Annual Meeting in Boston June 4–6, gathering TMS providers and researchers from around the world. The meeting served as the launchpad for major announcements from Neuronetics, BrainsWay, and MagVenture.
Read more →Neuronetics presented new real-world evidence from its TrakStar patient database at the 2026 Clinical TMS Society Annual Meeting, including NeuroStar effectiveness by age and sex, outcomes in adolescents aged 12–14, and a plenary on maintenance therapy.
Read more →MagVenture announced FDA clearance for accelerated TMS protocols to treat major depressive disorder in adults, allowing multiple sessions per day so a full course can be completed in days rather than the traditional four to six weeks.
Read more →Neuronetics announced a strategic collaboration with ANT Neuro to integrate image-guided neuronavigation into NeuroStar Advanced Therapy, offering ANT Neuro's visor2 system alongside NeuroStar for real-time coil targeting.
Read more →BrainsWay reported Q1 2026 revenue of $15.5 million, up about 35% year over year, and net income of $2.3 million. The company shipped a record 117 Deep TMS systems and reiterated full-year guidance of $66–68 million.
Read more →MagVenture launched MagVenture Go, a compact and mobile TMS system built on the MagPro R20 platform that supports both rTMS and iTBS protocols, aimed at clinics needing flexible, movable treatment capacity.
Read more →Neuronetics reported Q1 2026 revenue of $34.5 million, up 8% year over year. U.S. clinic revenue rose 15% to $21.5 million, and the company shipped 34 NeuroStar systems in the U.S., a 10% increase over Q1 2025.
Read more →A multicenter randomized trial is testing the Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol for postpartum depression across four U.S. sites, led by Thalia Robakis, MD, PhD, of the Icahn School of Medicine at Mount Sinai.
Read more →A six-site replication of the Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol reported 79% remission at four weeks in patients who had failed at least three prior antidepressants.
Read more →BrainsWay publicized an expanding set of U.S. payer policies that allow trained psychiatric mental health nurse practitioners to order, supervise, and administer TMS therapy, led by Optum Behavioral Health's policy covering about 34.8 million commercial lives.
Read more →The Medical University of South Carolina announced it is the first hospital system to offer Stanford Neuromodulation Therapy (SAINT), an accelerated form of TMS that can treat severe treatment-resistant depression in days rather than weeks, citing roughly 80% remission by day five.
Read more →Aetna updated its clinical policy bulletin to cover accelerated and SAINT-style TMS protocols without requiring patients to first complete a standard six-week course.
Read more →Optum, UnitedHealthcare, and United Behavioral Health updated their TMS clinical policy to let psychiatric mental health nurse practitioners order, supervise, and administer TMS therapy. The change, effective March 17, 2026, applies across 26 states and Washington, D.C.
Read more →An FDA advisory committee voted 9-2 in favor of expanding TMS labeling to include adolescents aged 15-21 with treatment-resistant depression.
Read more →A 184-patient sham-controlled trial reported clinically meaningful pain reductions in patients with chronic neuropathic pain following five weeks of motor cortex TMS.
Read more →A narrative review in Brain Sciences synthesized the neurobiology behind TMS for smoking cessation, concluding that active rTMS/deep TMS targeting prefrontal circuits reduces craving and cigarette consumption and may increase short-term abstinence versus sham.
Read more →A randomized trial conducted in three urban emergency departments found a single accelerated TMS session reduced acute suicidal ideation scores within 24 hours.
Read more →Hologic acquired Danish TMS device maker MagVenture for $1.2 billion, the largest M&A transaction in the TMS sector to date.
Read more →A Stanford-led study found 20 sessions of theta burst TMS improved working memory in healthy older adults, with effects persisting at one month.
Read more →A 220-patient randomized trial found six weeks of TMS reduced postpartum depression symptoms with response rates comparable to antidepressants, without exposing breastfeeding infants to medication.
Read more →The FDA cleared single-pulse TMS devices for acute treatment of migraine without aura, expanding from the previous label limited to migraine with aura.
Read more →The FDA issued warning letters to several websites marketing TMS-like devices direct to consumers without prescription, citing risks from unsupervised use.
Read more →A 412-patient European trial reported that contralesional inhibitory TMS combined with standard rehabilitation produced significantly better motor recovery at 90 days post-stroke than rehabilitation alone.
Read more →The Department of Veterans Affairs updated its national clinical guidance to cover TMS for PTSD as a primary indication, regardless of whether comorbid depression is present.
Read more →A 60-patient pilot trial reported clinically meaningful weight stabilization and reduced rumination in patients with severe enduring anorexia nervosa following 30 sessions of dorsomedial prefrontal cortex TMS.
Read more →An AHRQ-commissioned cost-effectiveness analysis found TMS is cost-effective compared with continued sequential antidepressant trials for treatment-resistant depression.
Read more →A meta-analysis of 42 randomized controlled trials with 4,200 patients found intermittent theta burst stimulation produces equivalent depression outcomes to standard 10Hz TMS in roughly a third of the session time.
Read more →A 308-patient pivotal trial reported clinically meaningful tinnitus reduction at 12 weeks with a personalized TMS protocol, supporting an FDA submission expected in 2026.
Read more →Neuronetics reported positive topline results from its pivotal trial of NeuroStar TMS in adolescents with treatment-resistant depression.
Read more →Leading TMS device manufacturers Neuronetics and BrainsWay reached a cross-licensing agreement ending a multi-year patent dispute over coil designs.
Read more →A national survey of TMS clinics found 60% report difficulty hiring qualified operators, prompting calls for standardized certification pathways.
Read more →A 380-patient NIH-funded study found TMS can be safely used in bipolar depression when patients are stable on mood stabilizers, with mania-switch rates comparable to background population risk.
Read more →Magnus Medical raised $90 million in Series C funding to scale commercial deployment of its SAINT-style accelerated TMS protocol.
Read more →A 180-patient Phase II trial reported reduced self-reported cocaine use and craving following a four-week course of left dorsolateral prefrontal cortex TMS in patients pursuing abstinence.
Read more →The FDA cleared an updated, shorter deep TMS protocol for adult smoking cessation, reducing the standard course from six weeks to three.
Read more →Cigna updated its behavioral health policy to cover deep TMS for OCD as a primary treatment option, removing the prior requirement for failed antidepressant trials.
Read more →A 215-patient multi-site trial reported significant anxiety reductions in patients with generalized anxiety disorder following six weeks of right dorsolateral prefrontal cortex TMS.
Read more →A Phase II trial reported 78% remission at four weeks for combined TMS and intravenous ketamine compared with 45% for TMS alone and 39% for ketamine alone.
Read more →A 76-patient pilot study found four weeks of TMS produced clinically meaningful improvements in attention and processing speed in patients with persistent post-COVID cognitive symptoms.
Read more →Six state Medicaid programs added or expanded coverage for TMS in the first half of 2025, bringing total state coverage to 38 states.
Read more →A UMass-led analysis of 12,000 patients treated in community clinics found response and remission rates exceeded those reported in industry-sponsored randomized trials.
Read more →The AMA added two new CPT codes that distinguish theta burst stimulation from standard 10Hz TMS, supporting differential payer reimbursement and tracking.
Read more →The FDA granted breakthrough device designation for a TMS protocol targeting cognitive symptoms in mild Alzheimer's disease, expediting review of pivotal trial data.
Read more →A 54-patient pilot study reported reductions in affective instability and impulsivity in patients with borderline personality disorder following four weeks of dorsolateral prefrontal cortex TMS.
Read more →CMS proposed updated reimbursement rates for TMS CPT codes that would link a portion of payment to patient-reported outcome data submitted by treating clinics.
Read more →The FDA cleared an expanded indication for Neuronetics' NeuroStar to include anxious depression, the first device-specific clearance for this subtype.
Read more →A pediatric TMS safety registry reported no seizures or serious adverse events across 1,200 adolescents treated for depression at academic medical centers.
Read more →A 12-site sham-controlled trial of 360 adults with ADHD found six weeks of prefrontal TMS improved attention and working memory in patients who were not currently taking stimulant medications.
Read more →A 48-patient pilot trial reported reduced tremor amplitude in patients with essential tremor following 10 sessions of cerebellar TMS.
Read more →A national survey found 73% of psychiatrists now refer patients for transcranial magnetic stimulation, a substantial increase from 41% in a comparable 2020 survey.
Read more →The UK National Institute for Health and Care Excellence issued positive guidance recommending NHS coverage of TMS for fibromyalgia pain, pending cost-effectiveness review.
Read more →CMS issued guidance encouraging Medicare Advantage plans to adopt standardized TMS prior authorization criteria, addressing wide variability that had created access barriers.
Read more →NeuroSphere received FDA clearance for the first home-use TMS device for depression maintenance in previously-treated patients, requiring clinic enrollment and remote monitoring.
Read more →A 96-patient sham-controlled trial reported reduced binge-purge frequency in bulimia nervosa following four weeks of dorsolateral prefrontal cortex TMS.
Read more →A systematic review of TMS during pregnancy across 22 studies and roughly 380 pregnancies found no signal of increased risk to mother or fetus.
Read more →The Clinical TMS Society released results from the first comprehensive registry of real-world TMS outcomes, finding 55% response and 31% remission rates across 50,000 patients.
Read more →A 12-month follow-up study of patients treated with deep TMS for obsessive-compulsive disorder found 62% of initial responders maintained meaningful improvement at one year.
Read more →CMS authorized Medicare reimbursement for transcranial magnetic stimulation delivered under telehealth physician supervision in rural and underserved areas.
Read more →Disclaimer: News items are for informational purposes only and do not constitute medical advice. Always consult a qualified healthcare provider regarding treatment decisions.
Get weekly updates on new clinics, insurance coverage, and treatment advances.
With all this promising research, see if TMS therapy is right for you.
Cigna TMS Coverage 
UnitedHealthcare Coverage 
Kaiser Permanente Coverage Get instant access to our comprehensive guide
